Open AccessThe role of splicing factor PRPF8 in breast cancer
Author(s) -
Difei Cao,
Jiaying Xue,
Guoqing Huang,
Jing An,
Weiwei An
Publication year - 2022
Publication title -
technology and health care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.281
H-Index - 44
eISSN - 1878-7401
pISSN - 0928-7329
DOI - 10.3233/thc-thc228028
Subject(s) - spliceosome , rna splicing , biology , cancer research , haploinsufficiency , breast cancer , cancer , gene , genetics , phenotype , rna
BACKGROUND: Alternative splicing is a mechanism to produce different proteins with diverse functions from one gene. Many splicing factors play an important role in cancer progression. PRPF8 is a core protein component of the spliceosome complex, U4/U6-U5 tri-snRNP. OBJECTIVE: However, PRPF8 involved in mRNA alternative splicing are rarely included in the prognosis. METHODS: We found that PRPF8 was expressed in all examined cancer types. Further analyses found that PRPF8 expression was significantly different between the breast cancer and paracancerous tissues. RESULTS: Survival analyses showed that PRPF8-high patients had a poor prognosis, and the expression of PRPF8 is associated with distant metastasis-free survival (DMFS) and post progression survival (PPS). Gene Set Enrichment Analysis (GSEA) has revealed that PRPF8 expression is correlated with TGF-β, JAK-STAT, and cell cycle control pathways. Consistent with these results, upon PRPF8 silencing, the growth of MCF-7 cells was reduced, the ability of cell clone formation was weakened, and p21 expression was increased. CONCLUSIONS: These results have revealed that PRPF8 is a significant factor for splicing in breast cancer progression.